floblu14
3 days ago
From BIOWORLD -
Infection
Enanta Pharmaceuticals describes new PL-pro
July 22, 2024
Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections. [Subscription needed]
https://www.bioworld.com/articles/710689-enanta-pharmaceuticals-describes-new-pl-pro?v=preview
floblu14
4 days ago
FWIW -
Friday, July 19, 2024 - A possible WIN for ENTA?
Reply to Response to Motion Fri 07/19 4:10 PM
SEALED REPLY in Support of 296 MOTION to Compel Defendant Pfizer Inc. to Produce Documents and Provide Deposition Testimony filed by Enanta Pharmaceuticals, Inc..(Cook, Savannah)
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
floblu14
4 weeks ago
IMHO - all these patents would be a significant value incentive for a merger or a buyout -
As of June 25, 2024 -
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Type: Grant
Filed: December 2, 2022
Date of Patent: June 25, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
https://patents.justia.com/patent/12018017
A series of studies using ASK1-deficient mice have indicated that ASK1 plays important roles in many stress-related diseases, including cardiovascular and neurodegenerative diseases, suggesting that small compounds that inhibit ASK1 activity could possibly be used for the amelioration of the development and/or progression of these diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491083/
floblu14
1 month ago
Might as well continue to list patents as they are granted. Who know what leverage they'll have in a potential acquisition or merger?
Hepatitis B antiviral agents
Patent number: 12011425
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 25, 2023
Date of Patent: June 18, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
floblu14
1 month ago
FWIW - Addendum - Barbara Fiacco - ENTA, if only -
Represented Dana-Farber as lead counsel in second case against Bristol-Myers Squibb and Ono Pharmaceuticals, asserting claims for unjust enrichment and unfair competition for depriving Dana-Farber of its co-ownership rights under eight patents directed to cancer immunotherapy. On the eve of trial, in the face of Dana-Farber’s claim for hundreds of millions of dollars in damages, Defendants settled, making a substantial lump sum payment to Dana-Farber and agreeing to make potential additional payments, contingent on future events.
https://foleyhoag.com/people/fiacco-barbara/#Experience
floblu14
1 month ago
ENTA has an outstanding litigator in their representation - Barbara Fiacco
Quote - The following Foley Hoag partners were also recognized for excellence in the industry in the following jurisdictions, and were described by IAM as:
Barbara Fiacco (National) and Donald Ware (MA) ranked in the Gold tier for litigation.
“Two of the most high-quality trial lawyers Boston has to offer,” and “A formidable team in life sciences litigation, securing multiple victories for the Dana-Farber Cancer Institute, resulting in significant payouts as well as co-ownership of groundbreaking cancer treatment patents.”
https://foleyhoag.com/news-and-insights/news/2024/june/foley-hoag-10-partners-recognized-in-2024-edition-of-iam-patent-1000/
https://foleyhoag.com/people/fiacco-barbara/
Here's the latest. Appears that ENTA is progressing well as of June 13. Comments?
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
floblu14
1 month ago
Two more for the books -
Patent number: 12006291
Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.
Type: Grant
Filed: January 10, 2023
Date of Patent: June 11, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Kaicheng Zhu, Tao Wang, Jiajun Zhang, Hui Cao, Ruichao Shen, Guoqiang Wang, George G. Wu, Yat Sun Or
Antiviral heterocyclic compounds
Patent number: 12006326
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: August 24, 2022
Date of Patent: June 11, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
June 11, 2024
Enanta Pharmaceuticals gets grant for macrocyclic compounds inhibiting coronavirus replication
....the patent outlines methods for treating viral infections, particularly coronavirus infections, by administering the disclosed compound. The methods include oral, subcutaneous, intravenous, or inhalation administration of the compound. Additionally, the patent covers inhibiting viral 3C protease or viral 3CL protease in a subject by administering the compound. The patent specifies the treatment of various strains of coronaviruses, including 229E, NL63, OC43, HKU1, SARS-CoV, and MERS coronavirus, highlighting the broad spectrum of antiviral activity claimed in the patent.
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-macrocyclic-compounds-inhibiting-coronavirus-replication/
DC15
2 months ago
It sounds like there may be some psychology involved, i.e., if there is more at stake, then in general a person will not want to be the sole decision maker. The follow-on psychological response is that when this goes to trial there will be a lot of average Joes on the jury hating big pharma, unless they credit Paxlovid with saving the lives of their loved ones, but of course those average Joes will be dismissed from the candidate pool.
dewophile
2 months ago
I think the odds of summary judgment in favor of PFE is higher than that for ENTA, but that the odds of no summary judgement for either is still the most likely outcome. The foundation for the active moiety does predate the pandemic after all bc the molecule is based on a structure designed for the virus that caused the earlier SARS outbreak in the early aughts. That said it does seem like the patent itself, if it stands, does cover paxlovid bc one of PFE's arguments that is public is that the patent was altered after the chemical structure of nirmatrelvir was revealed in 2021 so this could actually go in ENTA's favor as well if the judge really feel the patent shouldn't be invalidated
On April 6, 2021, at a virtual meeting of the American Chemical Society (“ACS”), Pfizer's scientists publicly revealed the chemical structure of nirmatrelvir.... It is Pfizer's position that significant revisions of the patent are based on Pfizer's work in developing nirmatrelvir, disclosed in the April 2021 presentation
https://casetext.com/case/enanta-pharm-v-pfizer-inc-2
dewophile
2 months ago
Thx Mouton
I guess there are 3 obvious outcomes here. PFE wins summary judgment and case is over, ENTA can win summary judgement, or the judge doesn't grant it to either party and it goes to trial. The second possibility, however small, would be hugely bullish, and the third option would as well bc once it goes to trial I would think PFE is more likely to settle
I guess a 4th option is the judge grants summary judgement in part narrowing the scope of what goes to trial?
always good to get a lawyer's opinion here thx - I have no idea how to handicap any of these possibilities frankly, but it seems at least so far today the remote possibility of a judgement in ENTA's favor in the next 2-3 months is dawning on some investors
dewophile
2 months ago
I don't but pretty much everything is sealed so I am not sure how much info this article could possibly have:
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
ENTA did seem to score a small victory proving most (but not all) of certain documents that PFE was hoping to get unsealed are in fact privileged. This is from early May:
https://casetext.com/case/enanta-pharm-v-pfizer-inc-2
On the present record before the Court, therefore, Enanta has not met its burden to prove that the redacted information is privileged. Nevertheless, this Court will give Enanta an opportunity to do so. Within two weeks, Enanta shall file declaration(s) supporting its assertions
Enanta was given time to support the redaction which was granted yesterday on most counts:
order Order Wed 05/29 1:09 PM
Magistrate Judge Jennifer C. Boal: ELECTRONIC ORDER entered. On May 7, 2024, this Court issued an order on Pfizer's Motion to Compel Production of Documents Improperly Withheld as Privileged (Docket No. 160 ). See Docket No. 247 . This Court ordered Enanta to submit declarations supporting its assertions of privilege with respect to Exhibits B, F (slide 2), L, O, R, and S. On May 21, 2024, Enanta submitted declarations supporting its assertion of privilege with respect to Exhibits B, F (slide 2), L (emails dated April 7, 2020, 3:16 PM, and April 7, 2020, 4:14 PM), R, and S and it withdrew its privilege assertions with respect to Exhibit O and Exhibit L (email dated April 7, 2020, 8:32 PM). After review and consideration of Enanta's submissions, this Court finds that the redactions to Exhibits B, F (slide 2), L (emails dated April 7, 2020, 3:16 PM, and April 7, 2020, 4:14 PM), R, and S are privileged. (Hutchins, Aaron)
floblu14
2 months ago
Do these patents really matter? (Contrary to my earlier post! )
Saturated spirocyclics as antiviral agents
Patent number: 11993600
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: December 6, 2022
Date of Patent: May 28, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph D. Panarese, Samuel Bartlett, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
floblu14
2 months ago
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
May 29, 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-participate-jefferies-global-healthcare-0
floblu14
2 months ago
FWIW - Good news for a potential buyer?
Enanta Pharmaceuticals sees highest patent filings and grants during February in Q1 2024
Excerpts:
Enanta Pharmaceuticals saw the highest growth of 199% in patent filings in February and 499% in grants in January in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 24% and grants by 499%.
Patents related to rare diseases and Covid-19 lead Enanta Pharmaceuticals's portfolio
Enanta Pharmaceuticals has the highest number of patents in rare diseases followed by, Covid-19 and climate change. For rare diseases, nearly 50% of patents were filed and 38% of patents were granted in Q1 2024.
Respiratory syncytial virus (rsv) infections related patents lead Enanta Pharmaceuticals portfolio followed by cardiovascular disease, and fatty liver disease
Enanta Pharmaceuticals has highest number of patents in respiratory syncytial virus (rsv) infections followed by cardiovascular disease, fatty liver disease, non alcoholic fatty liver disease (nafld), and non-alcoholic steatohepatitis (nash).
Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-patent-activity/?cf-view
dewophile
2 months ago
Thanks.
I just saw this amd thought there may be a counter suit.
Counter Claimant
Pfizer Inc.
Represented By
Thomas H.L. Selby
Williams & Connolly, LLP
contact info
Lee C. Bromberg
Mccarter & English, LLP
contact info
David I. Berl
Williams & Connolly, LLP
contact info
Wyley S. Proctor
Mccarter & English, LLP
contact info
Julie Tavares
Williams & Connolly LLP
contact info
Christopher Yeager
Williams & Connolly LLP
contact info
Erik Paul Belt
Mccarter & English, LLP
contact info
Counter Defendant
Enanta Pharmaceuticals, Inc.
Represented By
Donald R. Ware
Foley Hoag LLP
contact info
Barbara A. Fiacco
Foley Hoag LLP
contact info
Defendant
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
Represented By
Thomas H.L. Selby
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
DC15
2 months ago
I have not heard of any countersuit. It looks to me like the schedule of events I relayed on September 1, 2023 has been fulfilled:
Deadline for completion of expert depositions by April 12, 2024. Deadline for summary judgment motions and Daubert motions May 10, 2024. Deadline to file oppositions to summary judgment motions and oppositions to Daubert motions March 31, 2024. Deadline to file replies in support of summary judgment motions and replies in support of Daubert motions June 14, 2024
Are there any clowns anywhere?